MDxHealth Announces its Ordinary and Extraordinary General Shareholders’ Meetings
26 April 2022 - 6:00AM
MDxHealth Announces its Ordinary and Extraordinary General
Shareholders’ Meetings
NEWS RELEASE - REGULATED
INFORMATION 25
April 2022, 10:00 p.m.
CET
MDxHealth Announces its
Ordinary and Extraordinary
General Shareholders’ Meetings
IRVINE, CA, and
HERSTAL, BELGIUM – 25 April 2022
– MDxHealth SA (Nasdaq and Euronext Brussels: MDXH)
("MDxHealth" or the "Company"), a
commercial-stage precision diagnostics company, today invites the
holders of securities issued by the Company to its ordinary and
extraordinary general shareholders' meetings that will be held on
Wednesday, 25 May 2022 at 10:00 a.m., Belgian time.
The items on the agenda of the ordinary and
extraordinary general shareholders' meetings include the proposed
approval of a number of resolutions relating to the financial year
ended on 31 December 2021, as well as the issuance of a new share
option plan called the "2022 Share Option Plan".
In light of the COVID-19 pandemic and the
measures possibly imposed by the Belgian government to deal with
this pandemic, which may (still) be in effect on Wednesday 25 May
2022 (i.e., the scheduled date of the shareholders' meetings of the
Company), the board of directors recommends holders of securities
issued by the Company that wish to participate to the general
shareholders' meetings make use, as much as practically possible,
of the right to vote through voting by mail or by means of a
written proxy to the chair of the board of directors.
In order to participate to the ordinary and
extraordinary general shareholders’ meetings of the Company, the
holders of securities issued by the Company must comply with
Article 7:134, §2, first indent of the Belgian Companies and
Associations Code and the articles of association of the Company,
and fulfill the formalities described in the convening notice. The
convening notice, forms and other documents relating to the
ordinary and extraordinary general shareholders’ meetings can be
consulted on the Company’s website.
The Company recommends holders of its securities
to use e-mail for all communication with the Company regarding the
general shareholders' meetings. The Company's email address for
such communication is: agsm@mdxhealth.com.
About MDxHealth®
MDxHealth is a commercial-stage precision
diagnostics company that provides actionable molecular diagnostic
information to personalize the diagnosis and treatment of cancer.
The Company's tests are based on proprietary genetic, epigenetic
(methylation) and other molecular technologies and assist
physicians with the diagnosis of urologic cancers and prognosis of
recurrence risk. The Company's European headquarters are in
Herstal, Belgium, with laboratory operations in Nijmegen, The
Netherlands, and U.S. headquarters and laboratory operations based
in Irvine, California. For more information,
visit mdxhealth.com and follow us on social media
at: twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.
For more information:
|
MDxHealth info@mdxhealth.com |
|
Important informationThe
MDxHealth logo, MDxHealth, ConfirmMDx and SelectMDx are trademarks
or registered trademarks of MDxHealth SA ("MDxHealth"). All other
trademarks and service marks are the property of their respective
owners.
Mdxhealth (LSE:0O8G)
Historical Stock Chart
From Jan 2025 to Feb 2025
Mdxhealth (LSE:0O8G)
Historical Stock Chart
From Feb 2024 to Feb 2025
